General Information of Drug (ID: DMG7SQK)

Drug Name
Rescinnamine Drug Info
Synonyms
Anapral; Anaprel; Apolon; Apoterin; Cartric; Cinamine; Cinatabs; Cinnaloid; Cinnasil; Moderil; Normorescina; Paresinan; Raupyrol; Raurescin; Raurescine; Recinnamine; Recitensina; Rescaloid; Rescamin; Rescidan; Rescin; Rescinamina; Rescinnamin; Rescinnamina; Rescinnaminum; Rescinpal; Rescisan; Rescitens; Resealoid; Reserpinene; Reserpinin; Reserpinine; Resipal; Reskinnamin; Rozex; Scinnamina; Tenamine; Tuareg; Apoterin S; Methyl trimethoxycinnamoylreserpate; Rescinnamina [DCIT]; Trimethoxy cinnamoyl reserpate de methyl; Trimethoxy cinnamoyl reserpate de methyl [French]; Trimethoxycinnamoyl methyl reserpate; Tsuruselpi S; Anaprel (TN); Cinnasil (TN); Moderil (TN); NP-011016; Rescinamina [INN-Spanish]; Rescinnamine (VAN); Rescinnaminum [INN-Latin]; Resepinine (C35 alkaloid); Reserpinine (C35 alkaloid); Reserpinine (VAN); Tsuruselpi S (TN); Rescinnamine (JAN/INN); Rescinnamine [BAN:INN:JAN]; Methyl reserpate 3,4,5-trimethoxycinnamic acid ester; Reserpic acid methyl ester 3,4,5-trimethoxycinnamate; Methyl 18-O-(3,4,5-trimethoxycinnamoyl)reserpate; O-(3,4,5-Trimethoxy-trans-cinnamoyl) methyl reserpate; 3,4,5-Trimethoxycinnamic acid, methyl reserpate; 3,4,5-Trimethoxycinnamoyl methyl reserpate; 3,4,5-Trimethylcinnamic acid, ester with methyl reserpate; 3,4,5-Trimethylcinnamoyl methyl reserpate
Indication
Disease Entry ICD 11 Status REF
Hypertension BA00-BA04 Approved [1]
Therapeutic Class
Antihypertensive Agents
Cross-matching ID
PubChem CID
5280954
ChEBI ID
CHEBI:28572
CAS Number
CAS 24815-24-5
TTD Drug ID
DMG7SQK
VARIDT Drug ID
DR01190

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DOT
Drug Status:
Approved Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Enalapril DMNFUZR Congestive heart failure BD10 Approved [5]
Spirapril DM5XLTY Hypertension BA00-BA04 Approved [6]
Captopril DM458UM Chronic heart failure BD1Z Approved [7]
Benazepril DMH1M9B Hypertension BA00-BA04 Approved [8]
Moexipril DM26E4B Hypertension BA00-BA04 Approved [9]
Ramipril DM2R68E Acute heart failure BD10-BD13 Approved [10]
Perindopril DMOPZDT Hypertension BA00-BA04 Approved [11]
Trandolapril DM4L6EU Chronic heart failure BD1Z Approved [12]
Fosinopril DM9NJ52 Chronic heart failure BD1Z Approved [13]
Lisinopril DMUOK4C Chronic heart failure BD1Z Approved [14]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Flupentixol DM0DJ9O Schizophrenia 6A20 Approved [15]
Sertraline DM0FB1J Coronary heart disease BA80.Z Approved [16]
Crizotinib DM4F29C Non-small-cell lung cancer 2C25.Y Approved [17]
Lamotrigine DM8SXYG Bipolar disorder 6A60 Approved [18]
Cepharanthine DM9Y5JB N. A. N. A. Approved [19]
Itraconazole DMCR1MV Aspergillosis 1F20 Approved [20]
Clozapine DMFC71L Schizophrenia 6A20 Approved [21]
Midostaurin DMI6E0R Acute myeloid leukaemia 2A60 Approved [22]
Trifluoperazine DMKBYWI Anxiety Approved [23]
Olanzapine DMPFN6Y Bipolar depression Approved [21]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Metoclopramide DMFA5MY Nausea MD90 Approved [24]
Quinidine DMLPICK N. A. N. A. Approved [25]
Verapamil DMA7PEW Angina pectoris BA40 Approved [26]
Erythromycin DM4K7GQ Acne vulgaris ED80 Approved [27]
Clarithromycin DM4M1SG Acute maxillary sinusitis Approved [27]
Disopyramide DM5SYZP Long QT syndrome BC65.0 Approved [28]
Propranolol DM79NTF Angina pectoris BA40 Approved [29]
Amiodarone DMUTEX3 Tachyarrhythmias BC71 Approved [30]
Dofetilide DMPN1TW Sinus rhythm disorder BC9Y Approved [31]
Flecainide DMSQDLE Tachyarrhythmias BC71 Approved [27]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Angiotensin-converting enzyme (ACE) TTL69WB ACE_HUMAN Inhibitor [2]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
ATP-dependent translocase ABCB1 (ABCB1) OTEJROBO MDR1_HUMAN Gene/Protein Processing [3]
Potassium voltage-gated channel subfamily H member 2 (KCNH2) OTZX881H KCNH2_HUMAN Gene/Protein Processing [4]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7098).
2 Colorimetric determination of indolic drugs. Pak J Pharm Sci. 2005 Apr;18(2):48-51.
3 A structure-function relationship among reserpine and yohimbine analogues in their ability to increase expression of mdr1 and P-glycoprotein in a human colon carcinoma cell line. Mol Pharmacol. 1995 Oct;48(4):682-9.
4 Why are most phospholipidosis inducers also hERG blockers?. Arch Toxicol. 2017 Dec;91(12):3885-3895. doi: 10.1007/s00204-017-1995-9. Epub 2017 May 27.
5 Determination of bezafibrate, methotrexate, cyclophosphamide, orlistat and enalapril in waste and surface waters using on-line solid-phase extracti... J Environ Monit. 2009 Apr;11(4):830-8.
6 Central angiotensin II controls alcohol consumption via its AT1 receptor. FASEB J. 2005 Sep;19(11):1474-81.
7 Using ACE inhibitors appropriately. Am Fam Physician. 2002 Aug 1;66(3):461-8.
8 Efficacy of benazepril hydrochloride to delay the progression of occult dilated cardiomyopathy in Doberman Pinschers. J Vet Intern Med. 2009 Sep-Oct;23(5):977-83.
9 Moexipril for treatment of primary biliary cirrhosis in patients with an incomplete response to ursodeoxycholic acid. Dig Dis Sci. 2010 Feb;55(2):476-83.
10 Knockouts model the 100 best-selling drugs--will they model the next 100 Nat Rev Drug Discov. 2003 Jan;2(1):38-51.
11 Fixed combination perindopril-amlodipine (Coveram) in the treatment of hypertension and coronary heart disease. Rev Med Liege. 2009 Apr;64(4):223-7.
12 Selective reduction of central pulse pressure under angiotensin blockage in SHR: role of the fibronectin-alpha5beta1 integrin complex. Am J Hypertens. 2009 Jul;22(7):711-7.
13 Angiotensin-converting enzyme inhibition and novel cardiovascular risk biomarkers: results from the Trial of Angiotensin Converting Enzyme Inhibition and Novel Cardiovascular Risk Factors (TRAIN) study. Am Heart J. 2009 Feb;157(2):334.e1-8.
14 Involvement of vascular angiotensin II-forming enzymes in the progression of aortic abdominal aneurysms in angiotensin II- infused ApoE-deficient m... J Atheroscler Thromb. 2009 Jun;16(3):164-71.
15 Characteristics of P388/VMDRC.04, a simple, sensitive model for studying P-glycoprotein antagonists. Cancer Res. 1994 Feb 1;54(3):730-7.
16 Michaelis-Menten kinetic analysis of drugs of abuse to estimate their affinity to human P-glycoprotein. Toxicol Lett. 2013 Feb 27;217(2):137-42. doi: 10.1016/j.toxlet.2012.12.012. Epub 2012 Dec 27.
17 Editor's Highlight: PlacentalDisposition and Effects of Crizotinib: An Ex Vivo Study in the Isolated Dual-Side Perfused Human Cotyledon. Toxicol Sci. 2017 Jun 1;157(2):500-509. doi: 10.1093/toxsci/kfx063.
18 Functional evaluation of polymorphisms in the human ABCB1 gene and the impact on clinical responses of antiepileptic drugs. Pharmacogenet Genomics. 2008 May;18(5):390-402. doi: 10.1097/FPC.0b013e3282f85e36.
19 Cepharanthine potently enhances the sensitivity of anticancer agents in K562 cells. Cancer Sci. 2005 Jun;96(6):372-6. doi: 10.1111/j.1349-7006.2005.00057.x.
20 Clinical pharmacokinetic monitoring of itraconazole is warranted in only a subset of patients. Ther Drug Monit. 2005 Jun;27(3):322-33. doi: 10.1097/01.ftd.0000150135.22645.ea.
21 Evaluation of antipsychotic drugs as inhibitors of multidrug resistance transporter P-glycoprotein. Psychopharmacology (Berl). 2006 Sep;187(4):415-23. doi: 10.1007/s00213-006-0437-9. Epub 2006 Jun 30.
22 Actions of the selective protein kinase C inhibitor PKC412 on B-chronic lymphocytic leukemia cells in vitro. Haematologica. 2002 Feb;87(2):167-76.
23 Characterization of the ATPase activity of the Mr 170,000 to 180,000 membrane glycoprotein (P-glycoprotein) associated with multidrug resistance in K562/ADM cells. Cancer Res. 1988 Sep 1;48(17):4926-32.
24 Comparison of the effects of metoclopramide and domperidone on HERG channels. Pharmacology. 2005 Apr;74(1):31-6. doi: 10.1159/000083234. Epub 2005 Jan 7.
25 Further insights into the effect of quinidine in short QT syndrome caused by a mutation in HERG. J Cardiovasc Electrophysiol. 2005 Jan;16(1):54-8. doi: 10.1046/j.1540-8167.2005.04470.x.
26 Automated tight seal electrophysiology for assessing the potential hERG liability of pharmaceutical compounds. Assay Drug Dev Technol. 2004 Oct;2(5):497-506. doi: 10.1089/adt.2004.2.497.
27 Refining the human iPSC-cardiomyocyte arrhythmic risk assessment model. Toxicol Sci. 2013 Dec;136(2):581-94. doi: 10.1093/toxsci/kft205. Epub 2013 Sep 19.
28 Pharmacology of the short QT syndrome N588K-hERG K+ channel mutation: differential impact on selected class I and class III antiarrhythmic drugs. Br J Pharmacol. 2008 Nov;155(6):957-66. doi: 10.1038/bjp.2008.325. Epub 2008 Aug 25.
29 Comparison of HERG channel blocking effects of various beta-blockers-- implication for clinical strategy. Br J Pharmacol. 2006 Mar;147(6):642-52. doi: 10.1038/sj.bjp.0706508.
30 Inhibitory effects of the class III antiarrhythmic drug amiodarone on cloned HERG potassium channels. Naunyn Schmiedebergs Arch Pharmacol. 1999 Mar;359(3):212-9. doi: 10.1007/pl00005344.
31 Redox state dependency of HERGS631C channel pharmacology: relation to C-type inactivation. FEBS Lett. 2000 May 26;474(1):111-5. doi: 10.1016/s0014-5793(00)01586-6.